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Mathematical modelsIntravesical Bacillus Calmette–Guerin (BCG) vaccine is the preferred ﬁrst line treatment for non-muscle invasive
bladder carcinoma (NMIBC) in order to prevent recurrence and progression of cancer. There is ongoing need for
the rational selection of i) BCG dose, ii) frequency of BCG administration alongwith iii) synergistic adjuvant ther-
apy and iv) a reliable set of biochemical markers relevant to tumor response. In this review we evaluate cellular
andmolecularmarkers pertinent to the immunological response triggered by the BCG instillation and respective
mathematical models of the treatment. Speciﬁc examples ofmarkers include diverse immune cells, genetic poly-
morphisms, miRNAs, epigenetics, immunohistochemistry andmolecular biology ‘beacons’ as exempliﬁed by cell
surface proteins, cytokines, signaling proteins and enzymes. We identiﬁed tumor associated macrophages
(TAMs), human leukocyte antigen (HLA) class I, a combination of Ki-67/CK20, IL-2, IL-8 and IL-6/IL-10 ratio as
the most promising markers for both pre-BCG and post-BCG treatment suitable for the simulation studies.
The intricate and patient-speciﬁc nature of these datawarrants the use of powerful multi-parametral mathemat-
ical methods in combination with molecular/cellular biology insight and clinical input.
© 2015 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license
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Bladder cancer is the second most common cancer of the genitouri-
nary tract worldwide after prostate neoplasms [1]. It accounts for about
7% and 2% of new cancer cases in men and women, respectively [2].the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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thral resection of bladder tumor (TURBT), determination of the tumor
grade and the degree of tumor invasion [3]. However, prediction of
the clinical behavior and optimized treatment regimen for BC are
challenging up to this day. Approximately 70% of BCs are conﬁned to
layers above themuscularis propria and are termed non-muscle invasive
bladder cancer (NMIBC) [4].
Multiple clinical reports suggest that intravesical Bacillus Calmette–
Guerin (BCG) vaccine is the preferred 1st line treatment for the NMIBC
in order to prevent the recurrence and progression of cancer [5]. Identi-
ﬁcation of the BCG response markers that are clinically signiﬁcant,
disease-relevant, reproducible and easily accessible in the clinical set-
ting is of key importance in early treatment [6,7]. Repeated administra-
tion of BCG therapy has been suggested for patients with intermediate
and high risk of BC progression [8]. However, data from multiple
randomized clinical trials lack clear guidelines and rationale for the
maintenance schedule [9,10].
There is ongoing need for the rational selection of i) dose, ii) frequency
of BCG administration, iii) synergistic adjuvant therapy, and iv) bio-
markers relevant to tumor dynamics. A multi-disciplinary approach in-
volving clinical sciences, biology and mathematical modeling may yield
a real opportunity to increase disease-free survival of patients with
NMIBC. A similar strategy has been successfully applied to other areas
of oncology [11] including pancreatic cancer [12] and lymphoma [13].2. BCG: tentative mechanism of action
Activation of the innate immune system is a prerequisite for BCG-
induced responses. The interaction of BCGwith extracellularmatrix gly-
coproteins of the BC cells including ﬁbronectin and integrins is followed
by their internalization, recognition andprocessing by the host cell's im-
mune machinery. This is followed by production of cytokine and che-
mokine molecules as well as recruitment of leukocytes to the bladder
wall. A cascade of proinﬂammatory events is triggered allowing for
the ultimate detection of the resultingmediator molecules. Representa-
tive proteins include IL-1, IL-6, IL-8, IL-10, IL-12, IL-18, tumor necrosis
factor (TNF)-α, granulocyte-macrophage colony stimulating factor
(GM-CSF), macrophage inﬂammatory protein (MIP)-1α, macrophage-
derived chemokine (MDC), and interferon-inducible protein (IP)-10
[14,15]. The absence of standardization in BCG manufacturing and var-
iation in treatment protocols cause notable differences in the pheno-
type, antigenicity and clinical characteristics of the numerous
substrains of BCG used for the treatment of NMIBC [16].
BCG effect is mediated by multiple immune cells. BCG instillation is
followed by an increased number of macrophages in bladder cancer in-
ﬁltrates, the peri-tumoral bladder wall and urine [17–19]. BCG-
stimulated macrophages could directly interact with and affect BC
cells via the release of effector factors including TNF-α, IFN-γ and
apoptotic signaling molecules [20]. TH1 family cytokines (e.g. IFN-γ)
stimulatemacrophage cytotoxicitywhereas TH2 groupmolecules inhib-
it this effect. Neutrophils represent another important class of cells that
mediate tissue response to BCG infection via TLR2, TLR4 receptors and
adaptor protein MyD88. Neutrophil activation leads to the release of
TNF-related apoptosis-inducing ligand (TRAIL). TRAIL selectively stimu-
lates apoptosis in BC cells leading in part to the observed clinical effect.
There is a correlation between increased urinary levels of TRAIL and BCG
responsiveness in polymorphonuclear neutrophils (PMN) [21]. Release
of macrophages and neutrophils activates NK, CD4+ T, CD8+ T and
dendritic cells [22]. CD4 T cell analysis before each BCG instillation in
NMIBC patients revealed a 5-fold increase in T cell count by week 2/3,
and further increased 8-fold by week 4/5 [23]. Cytotoxicity of T and
NK cells toward BC is mediated by the major histocompatibility com-
plex (cytotoxic T lymphocytes (CTLs) or NK cells) [24]. Perforin, is a
key cytolytic protein produced by CTLs and NK cells. It is implicated in
selective pro-apoptotic elimination of the BC cells [25]. The highlyspecialized BCG-activated killer cell population neutralizes NK cell-
resistant BC cells using a similar lytic mechanism [26].
3. Biological markers: general notes
A pre-/post-BCG treatment classiﬁcation of biological markers has
been suggested [27]. Pre-treatment markers of importance in clinical
pathology include tumor size, multiplicity, stage/grade and history,
additional carcinoma(s) in situ (CIS) and number of TURs before BCG.
Whereas these parameters play a role in assessing the individual risk
of tumor progression and its invasiveness, there are no universally
applicable predictive markers of NMIBC. Several commercial tests
relying on biomarkers have been introduced into the clinic [28]. These
include BTA stat® (Bladder Tumor Antigen), BTA TRAK® (Human
Complement Factor H), NMP22 (Nuclear Matrix Protein)/Bladder
Chek,® ImmunoCyt™/uCyt™. Some of the assays are prone to yielding
false positive results, especially in patients exhibiting renal or prostate
inﬂammation. UroVysion™ test is aimed at analyzing aneuploidy in
chromosomes 3, 7, 17 and 9p21 using ﬂuorescence in situ hybridization
technique. While being quite efﬁcient in diagnosing NMIBC,
UroVysion™ is expensive [29].
3.1. Clinical pathology: tumor size and age effect
Of the multiple factors including age, gender, CIS, stage, number of
tumors, and tumor size for NMIBC patients treated with BCG, tumor
size of N3 cm in diameter was associated with BC recurrence, whereas
tumor stage (Ta or T1) was associated with tumor progression [30]. In
intermediate and high-risk NMIBC patients treated with BCG, older
cohort exhibited unfavorable long-term prognosis [31].
3.2. Cellular markers
Several studies suggested a marker of cellular proliferation Ki-67 to
be predictive of post-BCG tumor recurrence [32], contradicting earlier
data [33]. Further attempts to clarify this controversy were focused on
analyzing combination of Ki-67 with additional biomolecules. In a
recent study, CK20 expression was signiﬁcantly correlated with
recurrence-free survival (RFS). Ki-67 was the only marker signiﬁcantly
associated with progression-free survival (PFS). The combination of
CK20 and Ki-67 was indicative of BC aggressiveness showing signiﬁ-
cantly worse PFS and cancer-speciﬁc survival (CSS) in tumors with
high proliferation index [34].
The correlation between tumor associated macrophages (TAMs) in-
ﬁltrating BC in situ and response to BCG therapy using anti-CD68mono-
clonal antibody revealed that RFS was signiﬁcantly better in patients
with lower TAM count. Patients with lower cancer cell-to-lamina
propria TAM ratio had higher RFS [35].
3.3. Genetic and epigenetic markers
Detailed analysis of literature dealingwith gene polymorphisms and
their link to BCG response in the NMIBC patients has been conducted
[36]. Examples of gene polymorphisms that led to reduced RFS or in-
creased recurrence risk post-BCG include XPA, XPC, XPD, XPG, XPF,
ERCC1, ERCC2, ERCC6, XRCC1, XRCC4, APEX1, GSTM1, CCNB1, PON1, and
SLCO1B1. As anticipated, gene polymorphisms of multiple cytokines
were linked to the BCG treatment outcome, although RFS data were
controversial, as exempliﬁed by IL-6 [37]. More deﬁnitive outcome
was reported for the IL-8 (-251A/A) polymorphismwhichwas associat-
edwith an increased RFS in BCG-treated patients and for the PPARγ SNP
linked to a reduced recurrence risk [38]. Deregulation of FAS/FASL
system, namely FASL-844 T/C was implicated in the immune escape
affecting BCG therapy outcome [39].
Studies correlatingNRAMP1 and hGPX1 gene polymorphisms to BCG
response showed that the NRAMP1 D543N G:G genotype displayed
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RFS time post-BCG, although the study cohort was small [40]. XRCC1
is a scaffolding protein in base excision repair. Variants in XRCC1 gene
were suggested to alter protein structure/function or create alternative-
ly spliced protein inﬂuencing repair efﬁciency. Genotyping for three
polymorphic sites of XRCC1 at codons Arg194Trp (PvuII), Arg280His
(RsaI) andArg399Gln (MspI) yielded an association in heterozygous ge-
notype of codons 280 and 399 with BC risk. The A/A genotype of codon
399 was associated with the high risk for recurrence in BCG treated pa-
tients showing reduced RFS [41]. The increased risk of BC was observed
with the IL-1RN*2 and IFN-G + 874 A allele carriers in the post-BCG
group of patients. TGF-B TT and IFN-G+ 874 A carriers were associated
with reduced and enhanced risk of recurrence post-BCG, respectively
[42]. MicroRNAs (miRNAs) in serum and/or plasma have been intro-
duced as non-invasive biomarkers of BC. A selection of 15 miRNAs
was reported to be deregulated in different stage BC. Of these, 13
miRNAs were deregulated to the same extent in both NMIBC and
muscle-invasive BC. Three speciﬁc miRNAs, namely miR-9, miR-182
and miR-200b were associated with tumor aggressiveness and RFS
[43]. Changes in DNA methylation of tumor suppressor genes at the
early stages of BC have been introduced as markers of tumor stage,
aggressiveness and dynamics [44]. BC cell lines T24 and UM-UC-3
were treated with 5-aza-dC and 4-phenylbutyric acid (PBA) to mimic
epigenetic silencing of miRNA genes followed by the analysis of epige-
netic alteration in miRNA expression. miR-137, miR-124-2, miR-124-3,
andmiR-9-3 were frequentlymethylated in primary cancers suggestive
of their potential utility as BC biomarkers [45]. Themethylation analysis
for 18 tumor suppressor genes in urine samples revealed that PRDM2,
HLTF, ID4, DLC1, BNIP3, H2AFX, CACNA1G, TGIF and CACNA1A were
methylated in BC. Of these, CACNA1A gene methylation was directly
associated with tumor recurrence whereas PRDM2 and BNIP3 were
linked to recurrence and disease speciﬁc survival, respectively [46].
The amounts of methylated DNA aswell as themethylation frequencies
were assessed in serum of BC patients and healthy subjects. TIMP3
was found to be most frequently methylated, followed by APC, RARB,
and TIG1 genes. Both methylation levels for each gene site and the
number of methylated genes were increased in BC compared to
healthy individuals, however BCs at different stages of progression
could not be differentiated from non-malignant disease [47]. Despite
considerable progress in studies of genetic polymorphisms, miRNAs
and epigenetic markers associated with both pre-BCG treatment and
post-BCG treatment of NMIBC patients, more detailed, statistically
empowered, ethnically diverse and tumor stage-related studies are
needed to include these data into development of the individualized
therapeutic regimen.3.4. Molecular markers
3.4.1. Cell-surface proteins
BCs with high risk of recurrence/progression express the carbohy-
drate antigen sialyl-Tn (sTn). sTn and sTn-related antigen sialyl-6-T
(s6T) protein levels were associated with BCG response and increased
RFS [48]. Expression of podocalyxin-like anti-adhesive glycoprotein
(PODXL) in patients with Ta and T1 tumors was an independent
predictor of a reduced 2-year PFS [49]. Levels of tenascin-C (TN-C) in
voided urine correlated with the BC grade showing ca. 22 times higher
concentration in BC patients compared to healthy volunteers [50].
Human leukocyte antigen (HLA,MHC in humans) Class I plays a decisive
role in the recognition and elimination of tumor cells. It is down-
regulated in ca. 30% of BCs affecting presentation of a cancer antigen
to the immune system (ex., CTLs) [48]. More profound alterations
and a higher incidence of structural defects in HLA Class I expression
were found in post-BCG-recurrent tumors. Also, HLA Class I down-
regulation was a signiﬁcant prognostic factor in patients undergoing
BCG immunotherapy [51].3.4.2. Cytokines
IL-2 cytokine secreted by activated T-cells (CD4+) was introduced
as an independent predictive parameter of BCG response [52]. High
levels of IL-2 in urine post-BCG were directly associated with an in-
creased RFS. A signiﬁcant number of responders (70%) exhibited induc-
ibility of IL-2 mRNA in peripheral blood mononuclear cells which was
directly associated with an enhanced PFS. A time-dependent interplay
between IL-2 and IL-10 levels has been noted following BCG induction
and repeated booster vaccinations [53]. Based on these data, it was sug-
gested that repeated BCG alone may not be beneﬁcial for the general
population of NMIBC patients [54].
The IL-6/IL-10 ratio post-BCG has been evaluated in NMIBC patients
to reveal that subjects with the ratio value N.1 displayed higher RFS.
Both multivariate analyses of the IL-6/IL-10 ratio and the number of le-
sions were identiﬁed as independent predictors of BCG response [55].
BCG-stimulated C57BL/6 macrophages exhibited reduced killing of BC
MBT−2 andMB49 cells and produced a high level of IL-10, which corre-
lated with reduced production of TNF-α, IL-6 and NO. Macrophages
from C57BL/6 IL-10−/−mice exhibited increased killing of MB49 cells
suggesting that blockage of IL-10 could be beneﬁcial clinically [56].
A neutrophil chemotactic factor (IL-8) is secreted by macrophages
post-BCG inducing chemotaxis of primary neutrophils and other
granulocytes [57]. Levels of IL-8, matrix metallopeptidase 9 (MMP-9)
and syndecan in voidedurine fromBCpatientswere analyzed to suggest
that all proteins were signiﬁcantly elevated in BC subjects, however
only IL-8 was an independent factor for the detection of BC [58] contra-
dicting earlier studies [59]. High levels of IL-8 in the urine within the
ﬁrst 6 h after BCG administration were associated with an increased
RFS [60]. More careful, statistically empowered and standardized stud-
ies are needed to address this controversy.
The level of IL-17 production and neutrophil count in BCG-treated
bladderwas reduced inγδ T-cells-deﬁcient but not in CD4-cell-depleted
mice. The survival of BC-inoculated γδ T-cell-deﬁcient mice was not
improved by BCG treatment. It was concluded that IL-17-producing γδ
T-cells play a key role in the BCG-induced recruitment of neutrophils
to the bladder [61]. In addition to IL-8, BCG-activated macrophages are
reported to produce IFN-γ inducing factor (IL-18). Key responder cells
activated by IL-18 include NK and CTLs triggering secretion of IFN-γ.
Increased IL-18 levels in the urine measured within the ﬁrst 12 h after
BCG administration were signiﬁcantly associated with an increased
RFS [62]. Level of Gc-globulin (GC) in the urine of BC patients was
10-fold higher than in benign bladder conditions and normal controls
[63].
3.4.3. Other proteins
Protein expression for p53, pRb, PTEN, Ki-67, p27, FGFR3, and CD9
has been examined in order to assess their predictive value in tumor re-
currence and progression.Whereas increased p53 expression was asso-
ciatedwith tumor progression after BCG, noneof themarkers correlated
with RFS and PFS post-BCG [64]. In recent studies, CIS, gender and
cancer sub-stage (T1m/T1e) were themost important variables for pro-
gression whereas FGFR3 gene mutation, Ki-67, P53 and P27 expression
markers data were non-informative [65]. Histology data from the
NMIBC patients post-BCG or BCG + IFN-α combo suggested that
pRb expression was not associated with the outcome of BCG instillation
as opposed to the combination therapy. Neither p53 expression
nor p53 + pRb expression related to tumor response to BCG or
BCG + IFN-αwith respect to RFS and PFS [66].
Random peptide library of the circulating Ig's puriﬁed from a patient
after BCG has been screened to identify the corresponding target anti-
gens. Mycobacterium bovis heat-shock protein 65 (HSP-65) has been
identiﬁed as a serological marker of the humoral response to the treat-
ment. Increasing levels of IgA and IgG anti-HSP-65 titers directly corre-
lated with a positive outcome in BC patients [67]. The effect of BCG on
telomerase activity was examined in T24 and J82 BC cells. These were
co-cultured with BCG for 5 days to yield signiﬁcant decrease in
Fig. 1. Tentativemolecular cascade of immune response induced by intravesical BCG instillation. BCG is believed to cause tumor elimination by attachment of the BCG to speciﬁc receptors
on the urothelium (ex., ﬁbronectin, integrins) and initiation of inﬂammation reaction. This step leads to the release of multiple cytokines and chemokines (IL-1, IL-6, IL-8, etc.) from both
tumor and normal cells to attract a variety of immune cells into the bladder wall (dendritic cells (DCs), neutrophils, macrophages; key effectors in the BCG response aremarkedwith blue
boxes). Internalization of BCG triggers phagocytosis, apoptotic death via the release of TNF-related apoptosis-inducing ligand (TRAIL), maturation anddifferentiation of naïve CD4+T cells
into TH1 and/or TH2 cells that direct immune responses toward cellular or humoral immunity, respectively. The therapeutic effect of BCG depends on the proper induction of TH1 immune
responses. IL-10 inhibits TH1 immune responses whereas IFN-γ inhibits TH2 immune responses. Blocking IL-10 or inducing IFN-γ can lead to a TH1 dominated immunity that is essential
for BCG-mediated bladder cancer destruction. Detection and quantiﬁcation of these cells aswell as additional biological markers pre-BCG treatment (ex., single nucleotide polymorphism,
miRNAs, epigenetics, proteins) or after BCG installments in the clinical analytes is expected to provide better insight into cancer dynamics, its aggressiveness and optimize individual
treatment options.
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apoptotic cells was markedly increased suggesting that the reduction
of telomerase activity is related to the BCG treatment [68]. Inducible
nitric oxide synthase (iNOS) was found in the urothelial cells, macro-
phages and in the submucosa of post-BCGNMIBCpatients. Endogenous-
ly formedNOwas signiﬁcantly increased including a ten-fold increase in
mRNA expression for iNOS compared to healthy controls [69]. NMP-22
performedwell as amarker of low-grade lesions compared to the cytol-
ogy alone, however its levels were not affected by BCG therapy [70]. It
was speculated that the urine NMP-22 assay was likely to measure the
amount of cell turnover, including surface shedding from BCs and not
necessary any speciﬁc BC tumor antigen [71]. In a recent development,
a combination of cell cycle biomarker of aberrant growth, Mcm5 and
NMP22 in urine identiﬁed 95% of potentially life threatening diagnoses
[72]. HtrA1 is a secreted serine protease that processes IGF-binding pro-
teins and regulates cell growth. Expression of native and autocatalytic
forms of HtrA1 in human bladder tissue and urine has been analyzed
via immunohistochemistry. Signiﬁcantly higher amounts of both
HtrA1 forms were found in urine from BC patients compared to both
healthy subjects and patients with cystitis [73]. 6-Phosphofructo-2-
kinase/fructose-2,6-biphosphatase 4 (PFKFB4) regulates intracellular
levels of fructose 2,6-biphosphate, a key molecule in glycolysis. Expres-
sion levels of PFKFB4 mRNA in NMIBC tissue specimens were signiﬁ-
cantly higher in patients with high stage carcinoma and multiple
tumors as compared to low stage and single tumors [74]. There wasFig. 2. A) Schedule of maintenance treatment plan (Lamm's protocol): six-weekly intravesical i
for the 3 maintenance instillations until 52 weeks; B) simulation effects of a treatment regime
Shown is the tumor cells count as a function of time (500 days during and after therapy); C) si
tients. Time evolution of tumor cells up to 500 days. Maintenance treatmentwas carried outwit
blue solid line— CR (complete response), black solid line — PR (partial response), and green slstrong associations between lower UDP-glucuronosyltransferase 1A
(UGT1A) expression and the risk of recurrence in high-grade NMIBC.
In addition, the expression of UGT1A was positively and negatively
correlated with those of estrogen receptor-α and estrogen receptor-β,
respectively suggestive of its opposite regulation in normal bladder
tissue vs. BCs [75].
4. Mathematical models of cancer therapy
Several mathematical models of disease and respective therapeutic
interventions aimed at optimization of dosing and treatment regimen
have been introduced. Although this approach needs validation in on-
cology, there are multiple clinically relevant examples from other ther-
apeutic areas [76]. A computational model of glioma growth reliably
predicted the time to relapse using radiation alone and in combination
with chemotherapy [77]. A mathematical simulation in breast cancer
has been used to identify high-risk population, cancer screening strate-
gies, predicted tumor growth and optimized cancer treatment [78]. The
treatment outcome in orthotopic pancreatic tumor in vivo was de-
scribed computationally using in vitro data [12] and further expanded
to describe lymphoma [13]. Modeling approach to simulate tumor inva-
siveness andmetastasis based on both in vivo and in vitro data has been
introduced as well [79]. A comparison of experimental data for vaccina-
tion of HER-2/neu transgenic mouse and the respective mathematical
model suggested that the simulation accurately captured i) favorablenstillations of BCG (standard dose) and low dose of BCG (1/3 or 1/10 of the standard dose)
n (BCG only) with maintenance of BCG instillations (1/3 of standard dose) for 50 people.
mulated effect of BCG + IL-2 (induction) and BCG + IL-2 (maintenance) on 50 virtual pa-
h 1/10th of the standard BCG dose. Red solid line—NR (non-responders to the treatment),
ashed line — SD (stable disease).
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immune response in animals and iii) steady-state beneﬁcial immune re-
sponse maintained with fewer booster vaccinations [80]. Modeling
studies aimed to optimize the efﬁcacy of standard BCG protocol using
estimated in vitro parameters have been reported [81,82]. The model
took into consideration biological interactions between BCG, immune
cells and tumor cells post-BCG administration. Subsequent studies iden-
tiﬁed the dose of BCG and effective regimens that could be used to avoid
undesirable vaccination side-effects. The model allowed simulating the
effect of BCG pulses on the therapeutic outcome. Unfortunately, the pa-
rameters for the described model were taken from rather disparate
in vitro, in vivomurine and human clinical studies vs. individual patients
[83]. Simulation studies of NIMBC treatment with BCG or BCG + IL-2
combo used in situ data on tumor size, growth rate and immune
response assessment from the clinical set of estimated parameters
[84]. Thismodel described the dynamic interactions of tumor cells with-
in the bladder, the immune system, and the BCG immunotherapy
[85–87]. Combinations of the initial tumor size and varying growth
rates were tested using Lamm's maintenance protocol [88] (Fig. 2A)
and varying regiments of BCG. In the simulation studies, 50 NMIBC pa-
tients were kept on the Lamm's maintenance schedule and treated
with 1/3rd of the regular dose BCG as shown on Fig. 2B. The monother-
apy resulted in 38 patients showing complete response, whereas 11 pa-
tientswere refractive. Addition of IL-2 to BCGvaccine (standard dose for
the induction followed by 1/10th of the standard dose in the mainte-
nance treatment) yielded 48 complete responses, 1 partial response
and 1 non-responder (Fig. 2C). This outcome suggested that a mathe-
matical model could be of immediate clinical use to i) select a treatment
protocol including both reduced BCG dosing and maintenance schedul-
ing to minimize side effect(s) of vaccination; ii) predict the outcome
and iii) assess the need for synergistic agents on an individual basis.Fig. 3. A summary of pre- and post-BCG biological markers described in the text. The most5. Experimental markers for the mathematical model of NMIBC
Despite signiﬁcant advances in the identiﬁcation of biological
markers of NMIBC, very few of them hold promise as clinically relevant
and accurate predictors of success in BCG treatment. Several key reasons
include i) limited access to clinical data and patients; ii) lack of stan-
dardized bioanalytical procedures to evaluate biomarker levels; iii) eth-
nic, epigenetic, treatment backgrounds affecting gene polymorphism
and epigenetic markers; iv) opportunistic urogenital conditions; v) lon-
gitudinal relationship between disease progression and markers panel,
number of BCG installments, and adjuvant therapy; and vi) patient-
speciﬁc ‘ﬁngerprint’ of the disease.
The pro-inﬂammatory cascade induced byNMIBC alone or in combi-
nation with the BCG instillation involves multiple cell types and mole-
cules. In addition, time-resolved changes of these entities pre-/post-
BCG need to be considered. We selected several markers that could be
used as standalone parameters in the clinic and/or in the mathematical
models to determine the optimized treatment regimen (Fig. 3, bold)
using individual data from NMIBC patients.
Since the aforementioned cellular and molecular markers are likely
to be deregulated regardless of their pre-/post-vaccination collection
point, we recommend to analyze these as a panel throughout a patient's
individual history. Elevated IL-2 and IL-8 levels in the urine are promis-
ing predictive markers of BCG response. Notably, high urinary levels of
IL-8 within the ﬁrst 6 h post-BCG were associated with an increased
RFS. A direct interplay between cellular and molecular events occurring
post-BCG is illustrated by the IL-6/IL-10 ratio being a prognostic marker
of tumor recurrence (Fig. 1). As opposed to controversial data for Ki-67
alone, a combination of Ki-67/CK20was reported to be a reliable indica-
tor of BC aggressiveness. Down-regulation of HLA Class I in cancer cells
is disadvantageous for presentation of a cancer antigen to the immunepromising predictive markers and/or their combination for BCG response are in bold.
33A. Kiselyov et al. / BBA Clinical 4 (2015) 27–34system. Low levels of HLA class I were suggested as amarker in patients
undergoing BCG. The number of tumor associatedmacrophages (TAMs)
inﬁltrating the cancer area is one of several cellular markers predictive
of the treatment outcome pre-BCG. Once gene polymorphism, miRNAs
and epigenetic markers become more standardized and mainstream
in the clinic, they will be included in designing individual regiments
for the treatment of NMIBC. It is anticipated that the pre-BCG clinical pa-
rameters will allow for the proper calibration of the mathematical
model and customization of the treatment protocol. A post-BCG com-
parison of extrapolated and experimental outcome will enable further
reﬁnements of both simulation process and, more importantly, allow
for the optimization of patient-speciﬁc therapeutic approach.
6. Conclusions
In this past decade, we witnessed a growing interest toward mathe-
matical models of disease aimed at better understanding of i) key mo-
lecular targets suitable for intervention, ii) design and optimization of
treatment protocols and iii) regimen-related toxicities. In the area of
NMIBC, there is a real need for the rational selection of i) dose, ii) fre-
quency of BCG administration along with iii) synergistic adjuvant ther-
apy and iv) a reliable set of biochemical markers related to tumor
response. Addressing these challenges via amulti-disciplinary approach
involving simulation, molecular biology and clinical sciencemay yield a
real opportunity to increase disease-free and overall survival of patients.
Speciﬁcally, integration of systems biology data with in situ clinical evi-
dence and rationally designed treatment protocols are expected to re-
sult in much needed improvement(s) in the individual clinical
response to BCG and other relevant BC vaccines [89].
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